Prostate Cancer and Prostatic Diseases

Aims & Scope

Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide.

The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management.

Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate.

The journal covers the three main areas - prostate cancer, male LUTS and prostatitis.

Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books.

The journal also contains a calendar of forthcoming scientific meetings.

The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard.

A fast track system is available for topical articles of particular significance.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	5.8
2024	5.10

SJR (SCImago Journal Rank)

Year	Value
2024	1.962

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	81

Journal Rank

Year	Value
2024	1494

Journal Citation Indicator

Year	Value
2024	1687

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer

  Citation: 355

  Authors: Y

• Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

  Citation: 261

  Authors: E. David, Axel, Nathan, Bertrand, Antonio C. L., Arturo, Kurt, Frans M. J., Laurence

• Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia

  Citation: 248

  Authors: J, B, N, D

• Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting

  Citation: 242

  Authors: A V, G S, R W, H, W, R, W M, E, K E

• Increasing incidence of metastatic prostate cancer in the United States (2004–2013)

  Citation: 204

  Authors: A B, R S, S E, E M

• Pathologic progression of autochthonous prostate cancer in the TRAMP model

  Citation: 203

  Authors: JR, RJ, BA, NM

• ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

  Citation: 192

  Authors: B, S-H, D, A, C, A A, R, Y, G, T, G, D G, S, I A

• Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer

  Citation: 185

  Authors: Tobias, Olof, Markus, Henrik, Martin

• Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006

  Citation: 181

  Authors: N, E, M A, C, M, V, J, T, M L

• Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases

  Citation: 180

  Authors: P, R U, N, D, D R, D A

---